NASDAQ:CODX Co-Diagnostics (CODX) Stock Price, News & Analysis $1.09 -0.03 (-2.68%) As of 01:38 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsNews and TrendsOwnershipSEC Filings About Co-Diagnostics Stock (NASDAQ:CODX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Co-Diagnostics alerts:Sign Up Key Stats Today's Range$1.08▼$1.1550-Day Range$0.94▼$1.5652-Week Range$0.91▼$46.50Volume117,472 shsAverage Volume2.35 million shsMarket Capitalization$7.61 millionP/E RatioN/ADividend YieldN/APrice Target$67.50Consensus RatingModerate Buy Company Overview Co-Diagnostics, Inc. is a molecular diagnostics company headquartered in Salt Lake City, Utah. The company develops and commercializes diagnostic technologies and laboratory tests designed to identify infectious diseases and other medical conditions using polymerase chain reaction (PCR) and related molecular methods. Its core technology is the CoPrimer platform, which is intended to support the development of accurate, cost-efficient molecular diagnostic tests. Co-Diagnostics has marketed tests under the Logix Smart brand, including assays for respiratory and other infectious diseases. The company also developed molecular testing products related to COVID-19 and has pursued diagnostic applications in areas such as tuberculosis, mosquito-borne diseases, women’s health and oncology. Co-Diagnostics was founded in 2013 and serves customers through commercial, laboratory and distribution channels in the United States and international markets. Its products are designed for use by clinical laboratories, healthcare providers and other testing organizations, with availability varying by product, regulatory authorization and geography. Dwight E. Hurst is a co-founder and has served as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Co-Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreCODX MarketRank™: Co-Diagnostics scored higher than 40% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingCo-Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialCo-Diagnostics has a consensus price target of $67.50, representing about 5,986.6% upside from its current price of $1.11.Amount of Analyst CoverageCo-Diagnostics has only been the subject of 2 research reports in the past 90 days.Read more about Co-Diagnostics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Co-Diagnostics is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Co-Diagnostics is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCo-Diagnostics has a P/B Ratio of 0.12. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Co-Diagnostics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.47% of the float of Co-Diagnostics has been sold short.Short Interest Ratio / Days to CoverCo-Diagnostics has a short interest ratio ("days to cover") of 2.35, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Co-Diagnostics has recently increased by 42.11%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCo-Diagnostics does not currently pay a dividend.Dividend GrowthCo-Diagnostics does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for Co-Diagnostics this week, compared to 3 articles on an average week.Search Interest7 people have searched for CODX on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Co-Diagnostics insiders have not sold or bought any company stock.Percentage Held by Insiders2.30% of the stock of Co-Diagnostics is held by insiders.Percentage Held by Institutions14.99% of the stock of Co-Diagnostics is held by institutions.Read more about Co-Diagnostics' insider trading history. Receive CODX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Co-Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CODX Stock News HeadlinesCo-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe4 hours ago | prnewswire.comCo-Diagnostics Highlights Vector Smart® Momentum Following New Federal Initiative on Vector-Borne DiseaseOctober 7 at 9:00 AM | prnewswire.comElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt without major changes. As former head of the Department of Government Efficiency under President Trump, Musk saw firsthand how looming spending cuts could rattle markets and squeeze 401ks, IRAs, and TSPs. A preserved IRS provision may help everyday investors shield their retirement savings before the next wave of volatility hits.October 8 at 1:00 AM | American Hartford Gold (Ad)Co-Diagnostics to Showcase Co-Dx PCR Platform* and MTB Test at WHX Labs Johannesburg, Highlight Ebola Assay DevelopmentOctober 6 at 9:00 AM | prnewswire.comCo-Diagnostics Faces Repeated Annual Meeting Quorum DelaysSeptember 25, 2026 | tipranks.comCo-Diagnostics to Participate in Global Health Events During UN General Assembly WeekSeptember 23, 2026 | prnewswire.comCo-Diagnostics to Participate in Global Health Roundtable on Ebola and Outbreak InnovationSeptember 21, 2026 | prnewswire.comAnalysts Offer Insights on Healthcare Companies: Co-Diagnostics (CODX) and Amgen (AMGN)September 18, 2026 | theglobeandmail.comSee More Headlines CODX Stock Analysis - Frequently Asked Questions How have CODX shares performed this year? Co-Diagnostics' stock was trading at $5.56 at the beginning of 2026. Since then, CODX shares have decreased by 80.1% and is now trading at $1.1090. How were Co-Diagnostics' earnings last quarter? Co-Diagnostics, Inc. (NASDAQ:CODX) announced its earnings results on Thursday, August, 13th. The company reported ($1.46) earnings per share for the quarter, beating the consensus estimate of ($3.00) by $1.54. The firm earned $0.17 million during the quarter, compared to analyst estimates of $0.13 million. Co-Diagnostics had a negative trailing twelve-month return on equity of 210.99% and a negative net margin of 6,531.77%. Read the conference call transcript. When did Co-Diagnostics' stock split? Co-Diagnostics shares reverse split on the morning of Friday, January 2nd 2026.The 1-30 reverse split was announced on Tuesday, December 30th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 31st 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Co-Diagnostics IPO? Co-Diagnostics (CODX) raised $9 million in an IPO on Thursday, July 13th 2017. The company issued 1,300,000 shares at $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities served as the underwriters for the IPO. How do I buy shares of Co-Diagnostics? Shares of CODX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Co-Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Co-Diagnostics investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Moderna (MRNA), Inovio Pharmaceuticals (INO) and Novavax (NVAX). Company Calendar Last Earnings8/13/2026Today10/08/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (11m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CODX's financial health is in the Red zone, according to TradeSmith. CODX has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CODX CIK1692415 Webwww.codiagnostics.com Phone(801) 438-1036FaxN/AEmployees115Year Founded2013Price Target and Rating Average Price Target for Co-Diagnostics$67.50 High Price Target$90.00 Low Price Target$45.00 Potential Upside/Downside+6,081.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($10.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$46.90 million Net Margins-6,531.77% Pretax Margin-6,756.77% Return on Equity-210.99% Return on Assets-174.97% Debt Debt-to-Equity RatioN/A Current Ratio1.81 Quick Ratio1.52 Sales & Book Value Annual Sales$620 thousand Price / Sales12.29 Cash FlowN/A Price / Cash FlowN/A Book Value$9.14 per share Price / Book0.12Miscellaneous Outstanding Shares6,980,000Free Float6,820,000Market Cap$7.62 million OptionableNo Data Beta2.90 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:CODX) was last updated on 10/8/2026 by MarketBeat.com Staff. From Our PartnersNNVC Is Heading Into a Big MomentNanoViricides (NYSE American: NNVC) is moving NV-387 into a Phase II trial for Ebola in the Democratic Republi...Equiscreen | SponsoredAI learned to see and hear. Now this microcap is teaching it to smellMorgan Stanley projects the humanoid robotics market could hit $5 trillion by 2050, with over 1 billion robots...Capital Trends | SponsoredHOST Just Entered the AI Data Center Race in a BIG WayHost Digital Inc (NYSE American: HOST) has completed its merger with Healthy Choice Wellness Corp as of Septem...Trading Wire | SponsoredOminous New Day in America (Get Ready for it)A market forecaster with a 55-year track record - including calls on 1970s double-digit inflation, the 1980s S...Weiss Ratings | SponsoredWhy The Biggest Names in AI Are Heading To The ArcticGoogle contracted over 12 GW of energy last year and just announced a 15 billion dollar AI infrastructure inve...The Tomorrow Investor | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredInside a Former Merrill Lynch Advisor's Income PlaybookA former Merrill Lynch and Vanguard advisor spent 25 years watching one weekly options play generate consisten...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Co-Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Co-Diagnostics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
